- Home
- IMAB vs NMS Comparison
IMAB vs NMS Comparison
Compare IMAB & NMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- NMS
- Stock Information
- Founded
- IMAB 2014
- NMS 1993
- Country
- IMAB United States
- NMS United States
- Employees
- IMAB N/A
- NMS N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- NMS Finance Companies
- Sector
- IMAB Health Care
- NMS Finance
- Exchange
- IMAB Nasdaq
- NMS Nasdaq
- Market Cap
- IMAB 79.9M
- NMS 71.8M
- IPO Year
- IMAB 2020
- NMS N/A
- Fundamental
- Price
- IMAB $0.84
- NMS $12.30
- Analyst Decision
- IMAB Strong Buy
- NMS
- Analyst Count
- IMAB 3
- NMS 0
- Target Price
- IMAB $8.00
- NMS N/A
- AVG Volume (30 Days)
- IMAB 216.1K
- NMS 12.0K
- Earning Date
- IMAB 03-21-2025
- NMS 01-01-0001
- Dividend Yield
- IMAB N/A
- NMS 4.11%
- EPS Growth
- IMAB N/A
- NMS N/A
- EPS
- IMAB N/A
- NMS N/A
- Revenue
- IMAB $569,464.00
- NMS N/A
- Revenue This Year
- IMAB N/A
- NMS N/A
- Revenue Next Year
- IMAB N/A
- NMS N/A
- P/E Ratio
- IMAB N/A
- NMS N/A
- Revenue Growth
- IMAB N/A
- NMS N/A
- 52 Week Low
- IMAB $0.76
- NMS $9.21
- 52 Week High
- IMAB $2.00
- NMS $12.18
- Technical
- Relative Strength Index (RSI)
- IMAB 38.53
- NMS 37.62
- Support Level
- IMAB $0.78
- NMS $12.35
- Resistance Level
- IMAB $0.93
- NMS $12.40
- Average True Range (ATR)
- IMAB 0.07
- NMS 0.07
- MACD
- IMAB -0.01
- NMS -0.01
- Stochastic Oscillator
- IMAB 33.45
- NMS 0.00
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About NMS Nuveen Minnesota Quality Municipal Income Fund
Nuveen Minnesota Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Minnesota state income taxes and its secondary investment objective is the enhancement of portfolio value.